Escalating immunotherapy of multiple sclerosis

European Neurology

Volumn 42, Issue 3, 1999, Pages 121-127

  Rieckmann, P ^a,b   Toyka, K V ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

^b UNIVERSITY OF WÜRZBURG   (Germany)

Author keywords

Consensus; Evidence based medicine; Immunotherapy; Multiple sclerosis

Indexed keywords

AZATHIOPRINE; BETA INTERFERON; BETA1A INTERFERON; CORTICOSTEROID; CYCLOPHOSPHAMIDE; GLATIRAMER; IMMUNOGLOBULIN G; IMMUNOMODULATING AGENT; INTERFERON BETA SERINE; METHYLPREDNISOLONE; MITOXANTRONE;

ARTICLE; CLINICAL TRIAL; EVIDENCE BASED MEDICINE; HEALTH CARE COST; HUMAN; IMMUNOMODULATION; IMMUNOPROPHYLAXIS; IMMUNOTHERAPY; INTRAMUSCULAR DRUG ADMINISTRATION; MAJOR CLINICAL STUDY; MEDICAL INFORMATION; META ANALYSIS; MULTICENTER STUDY; MULTIPLE SCLEROSIS; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROPHYLAXIS; TREATMENT FAILURE;

ADJUVANTS, IMMUNOLOGIC; ADULT; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; AZATHIOPRINE; CYCLOPHOSPHAMIDE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON-BETA; MALE; METHYLPREDNISOLONE; MITOXANTRONE; MULTIPLE SCLEROSIS; PEPTIDES; PULSE THERAPY, DRUG;

EID: 0032846749     PISSN: 00143022     EISSN: None     Source Type: Journal    
DOI: 10.1159/000008084     Document Type: Article

References (39)

1. Report of the Quality Standards Subcommittee of the American Academy of Neurology: Practice advisory on selection of patients with multiple sclerosis for treatment with Betaseron. Neurology 1994;44:1537-1540.
2. Lublin FD, Reingold SC: Defining the clinical course of multiple slerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology 1996;46:907-911.
3. Kessinger A: Consensus conference on highdosc therapy with hematopoictic stem cell transplantation in diffuse large-cell lymphoma. Ann Oncol 1998;9(suppl 1):S23-S30.
4. Weeks J: Overview of outcomes research and management and its role in oncology practice. Oncology 1998;12(suppl 4): 11-30.
5. McQuay HJ, Moore A: Using numerical results from systematic reviews in clinical practice. Ann Intern Med 1997;126:712-720.
6. Multiple Sclerosis Therapy Consensus Group (MSTKG): Escalating immunomodulatory therapy of multiple sclerosis. Nervenarzt 1999; 70:371-386.
7. O'Riordan JI, Thompson AJ, Kingsley DPE, MacManus DG, Kendall BE, Rudge P. et al: The prognostic value of brain MRI in clinically isolated syndromes of the CNS - A 10-year follow-up. Brain 1998;121:495-503.
8. Kremenchutzky M, Baskerville J, Rice GPA, Ebers GC: Progressive relapsing and relapsing progressive multiple sclerosis: A re-evaluation (abstract P 2148). Multiple Sclerosis 1998;4: 372.
9. Trapp BD, Peterson J, Ransohoff RM, Rudick R, Mork S, Bo L: Axonal transcction in the lesions of multiple sclerosis. N Engl J Med 1998;338:278-285.
10. Goodkin DE, Bailly RC, Teetzen ML, Hertsgaard D, Beatty WW: The efficacy of azathioprine in relapsing-remitting multiple sclerosis. Neurology 1991;41:20-25.
11. IFNB Multiple Sclerosis Study Group: Interferon beta-lb in the treatment of multiple sclerosis: Final outcome of the randomized controlled trial. Neurology 1995;45:1277-1285.
12. Jacobs LD, Cookfair DL, Rudick RA, Herndon RM, et al: Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. Ann Neurol 1996;39:285-294.
13. PRISMS (Prevention of Relapses and Disability by Interferon Beta-1a Subcutaneously in Multiple Sclerosis) Study Group: Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. Lancet 1998;352:1498-1504.
14. Arnason BG, Dianzani F: Correlation of the appearance of anti-interferon antibodies during treatment and diminution of efficacy: summary of an International Workshop of Anti-Interferon Antibodies. J Interferon Cytokine Res 1998;18:639-644.
15. OWIMS Study Group: Interferon beta-1a in multiple sclerosis: Dose-dependent clinical and MRI efficacy. 123rd Annual Meeting of the American Neurological Association (abstract). Montreal, October 1998.
16. European Study Group on Interferon Beta-1b in Secondary Progressive MS, Kappos L, Miller D, Polman C, Pozzilli C, Thompson A: Placebo-controlled multicentre randomised trial of interferonß-1b in treatment of secondary progressive multiple sclerosis. Lancet 1998;352: 1491-1497.
17. Paty DW, and the Secondary Progressive Interferon beta-1a MS Study Group: Results of the 3-year, double-blind, placebo-controlled study of interferon beta-1a (Rebif) in secondary-progressive MS. J Neurol 1999;246(suppl 1): 1/15.
18. Bornstein MB, Miller A, Slagle S, Weitzman M, Crystal H, Drexler E, et al: A pilot trial of Cop I in exacerbating-remitting multiple sclerosis. N Engl J Med 1987;317:408-414.
19. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, et al: Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: Results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer I Multiple Sclerosis Study Group (see comments). Neurology 1995;45:1268-1276.
20. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, et al: Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. Neurology 1998;50:701-708.
21. Comi G, Filippi M. Copaxone MR1 Study Group: The effect of glatiramer acetate (Copaxone®) on disease activity as measured by cerebral MR1 in patients with relapsing-remitting multiple sclerosis (RRMS). Neurology 1999; 52:A289.
22. Dalakas MC: Intravenous immune globulin therapy for neurologic diseases. Ann Intern Med 1997;126:721-730.
23. Fazekas F, Deisenhammer F, Strasser-Fuchs S, Nahler G, Mamoli B: Randomised placebo-controlled trial of monthly intravenous immunoglobulin therapy in relapsing-remitting multiple sclerosis. Lancet 1997;349:589-593.
24. Achiron A, Gabbay U, Gilad R, Hassin-Baer S, Barak Y, Gornish M, et al: Intravenous immunoglobulin treatment in multiple sclerosis - Effect on relapses. Neurology 1998;50:398-402.
25. Sørensen PS, Wanscher B, Jensen CV, Schreiber K, Blinkenberg M, Ravnborg M, et al: Intravenous immunoglobulin G reduces MR1 activity in relapsing multiple sclerosis. Neurology 1998;50:1273-1281.
26. Van Engelen BG, Hommes OR, Pinckers A, et al: Improved vision after intravenous immunoglobulin in stable dcmyelinatingoptic neuritis. Ann Neurol 1992;32:834-835.
27. Yudkin P, Ellison GW, Ghezzi A, Goodkin DE, Hughes RA, McPherson K, et al: Overview of azathioprine treatment in multiple sclerosis. Lancet 1991;338:1051-1055.
28. Confavrcux C, Saddier P, Grimaud J, Moreau T, Adeleine P, Aimard G: Risk of cancer from azathioprine therapy in multiple sclerosis: A case-control study. Neurology 1996;46:1607-1612.
29. Fidler JM, Quinn de Joy S, Smith FR, Gibbons JJ: Selective immunomodulation by the antineoplastic agent mitoxantrone. II. Nonspecific adherent suppressor cells derived from mitoxantrone treated mice. J Neuroimmunol 1986; 136:2747-2754.
30. Edan G, Miller D, Clanet M, Confavreux C, Lyon Caen O, Lubetzki C, et al: Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: A randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 1997;62:112-118.
31. Millefiorini E, Gasperini C, Pozzilli C, D'Andrea F, Bastianello S, Trojano M, et al: Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. J Neurol 1997;244:153-159.
32. Hartung HP, Gonsette R, MIMS Study Group: Mitoxantrone in progressive multiple sclerosis (MS): A placebo-controlled, randomized, observer-blind European phase III multicenter study - Clinical results (abstract OR 207). Multiple Sclerosis 1998;4:325.
33. Koehler J, Beer K, Pette M: Mitoxantron-Therapie bei Multipler Sklerose. Akt Neurol 1998; 25:1-3.
34. The Canadian Cooperative Multiple Sclerosis Study Group: The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis. Lancet 1991; 337:441-446.
35. Weiner HL, Mackin GA, Orav EJ, Hafler DA, Dawson DM, Lapierre Y, et al: Intermittent cyclophosphamide pulse therapy in progressive multiple sclerosis: Final report of the Northeast Cooperative Multiple Sclerosis Treatment group. Neurology 1993;43:910-918.
36. Pette M, Hartung HP, Toyka KV: Cyclophosphamid in der Therapie der chronisch-progredienten Multiplen Sklerose - Kritische Analyse der vorliegenden Studien. Nervenarzt 1994;65: 271-274.
37. Fauci AS: The spectrum of vasculitis. Clinical, pathological, immunological, and therapeutic consideration. Ann Intern Med 1978;89:660-668.
38. Hohlfeld R, Toyka KV, Besinger UA, Gerhold B, Heininger K: Myasthenia gravis: Reactivation of clinical disease and of autoimmune factors after discontinuation of long-term azathioprine. Ann Neurol 1985;17:238-242.
39. Lockwood CM, Pinching AJ, Sweny P, Rees AJ, Pussell B, Uff J, Peters DK: Plasma-exchange and immunosuppression in the treatment of fulminating immune-complex crescentic nephritis. Lancet 1977;8002:63-67.